TP53 and neoplasm: In the present study, the aim was to uncover the precise mechanisms for activation of antitumor immunity by p53-armed oncolytic adenovirus OBP-702, focusing especially on the effects on DCs via tumor-derived exosomes secreted following OBP-702 treatment.